Physician profile
Mitchell B Shear
NPI 1801952510
$4,792.10
in general payments reported to CMS, 2019-2025
23 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $798 · 2021: $1,297 · 2022: $609 · 2023: $425 · 2024: $341 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.73 | 2021-2024 | Vraylar |
| Sanofi-Aventis U.S. LLC | $818.06 | 2019-2023 | |
| Glaxosmithkline, LLC. | $547.56 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $492.84 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $449.62 | 2019-2023 | |
| Allergan, INC. | $275.90 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.73 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $130.87 | 2019 | |
| Merck Sharp & Dohme LLC | $129.77 | 2020-2023 | Pifeltro, Dificid, Isentress |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.29 | 2021-2022 | |
| Novo Nordisk INC | $104.70 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $80.34 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.09 | 2023-2025 | Caplyta |
| Daiichi Sankyo INC. | $63.83 | 2021 | |
| Phathom Pharmaceuticals, INC. | $59.25 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $55.37 | 2019 | |
| Exact Sciences Corporation | $35.99 | 2023-2024 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $22.40 | 2025 | Vowst |
| Eisai INC. | $20.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.65 | 2024 | Zoryve |
| Amgen INC. | $18.03 | 2025 | Repatha |
| Althera Pharmaceuticals LLC | $17.31 | 2021 | |
| Linus Health, INC. | $14.77 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Shear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.